Pulmonx is expected to report Q3 2026 revenue of $23.1 million and a consensus EPS loss of $0.26, with the current stock price of $7.42 trading well below the average analyst price target of $14.25.
Investors are primarily focused on the growth of active U.S. hospital accounts and the associated Zephyr Valve procedure volumes for the quarter.
The company has been aggressively expanding its commercial team to increase physician adoption and penetrate the severe emphysema market more deeply. While international sales remain a stable contributor, U.S. commercial execution and the path toward cash-flow break-even are the critical themes for this reporting period.